Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor

Seung Woo Chung, Jeong uk Choi, Beom Seok Lee, Julia Byun, Ok Cheol Jeon, Seong Who Kim, In-San Kim, Sang Yoon Kim, Youngro Byun

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Existence of the genomically and epigenomically diverse subclones in a tumor severely limits the therapeutic efficacy of targeted agents. To overcome such a limitation, we prepared a novel targeted prodrug, EMC-DEVD-S-DOX, which comprises two important features: radiation-induced apoptosis targeting and albumin-binding properties. In particular, the prodrug binds circulating albumin after intravenous administration and then activated by caspase-3, which is upregulated from apoptotic cells that responded to radiotherapy. The prodrug was designed to bind circulating albumin to extend half-life and facilitate tumor accumulation in order to increase the possibility of contacting caspase-3, which is only transiently upregulated during apoptosis. Our results showed that EMC-DEVD-S-DOX had a prolonged half-life with enhanced tumor accumulation, which clearly benefited the therapeutic effect of the prodrug. Also, agreeing with the in vitro studies that showed ignorable cytotoxic effect in the absence of caspase-3, the prodrug was effective only when combined with radiotherapy without any noticeable systemic toxicity in vivo. Due to the highly selective action of EMC-DEVD-S-DOX independent to the complex genomic profiles of tumor, the prodrug would overcome the limitation of current targeted therapy and potentiate radiotherapy in the clinical oncology.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalBiomaterials
Volume94
DOIs
Publication statusPublished - 2016 Jul 1
Externally publishedYes

Fingerprint

Prodrugs
Caspases
Tumors
Albumins
Radiotherapy
Electromagnetic compatibility
Radiation
Cell death
Caspase 3
Neoplasms
Oncology
Half-Life
Apoptosis
Toxicity
Medical Oncology
Cells
Therapeutic Uses
Intravenous Administration
Therapeutics

Keywords

  • Albumin
  • Apoptosis
  • Caspase
  • Drug delivery
  • Prodrug
  • Radiotherapy

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor. / Chung, Seung Woo; Choi, Jeong uk; Lee, Beom Seok; Byun, Julia; Jeon, Ok Cheol; Kim, Seong Who; Kim, In-San; Kim, Sang Yoon; Byun, Youngro.

In: Biomaterials, Vol. 94, 01.07.2016, p. 1-8.

Research output: Contribution to journalArticle

Chung, Seung Woo ; Choi, Jeong uk ; Lee, Beom Seok ; Byun, Julia ; Jeon, Ok Cheol ; Kim, Seong Who ; Kim, In-San ; Kim, Sang Yoon ; Byun, Youngro. / Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor. In: Biomaterials. 2016 ; Vol. 94. pp. 1-8.
@article{2d05898f3e8a44c9a95c1bad0712f497,
title = "Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor",
abstract = "Existence of the genomically and epigenomically diverse subclones in a tumor severely limits the therapeutic efficacy of targeted agents. To overcome such a limitation, we prepared a novel targeted prodrug, EMC-DEVD-S-DOX, which comprises two important features: radiation-induced apoptosis targeting and albumin-binding properties. In particular, the prodrug binds circulating albumin after intravenous administration and then activated by caspase-3, which is upregulated from apoptotic cells that responded to radiotherapy. The prodrug was designed to bind circulating albumin to extend half-life and facilitate tumor accumulation in order to increase the possibility of contacting caspase-3, which is only transiently upregulated during apoptosis. Our results showed that EMC-DEVD-S-DOX had a prolonged half-life with enhanced tumor accumulation, which clearly benefited the therapeutic effect of the prodrug. Also, agreeing with the in vitro studies that showed ignorable cytotoxic effect in the absence of caspase-3, the prodrug was effective only when combined with radiotherapy without any noticeable systemic toxicity in vivo. Due to the highly selective action of EMC-DEVD-S-DOX independent to the complex genomic profiles of tumor, the prodrug would overcome the limitation of current targeted therapy and potentiate radiotherapy in the clinical oncology.",
keywords = "Albumin, Apoptosis, Caspase, Drug delivery, Prodrug, Radiotherapy",
author = "Chung, {Seung Woo} and Choi, {Jeong uk} and Lee, {Beom Seok} and Julia Byun and Jeon, {Ok Cheol} and Kim, {Seong Who} and In-San Kim and Kim, {Sang Yoon} and Youngro Byun",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.biomaterials.2016.03.043",
language = "English",
volume = "94",
pages = "1--8",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor

AU - Chung, Seung Woo

AU - Choi, Jeong uk

AU - Lee, Beom Seok

AU - Byun, Julia

AU - Jeon, Ok Cheol

AU - Kim, Seong Who

AU - Kim, In-San

AU - Kim, Sang Yoon

AU - Byun, Youngro

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Existence of the genomically and epigenomically diverse subclones in a tumor severely limits the therapeutic efficacy of targeted agents. To overcome such a limitation, we prepared a novel targeted prodrug, EMC-DEVD-S-DOX, which comprises two important features: radiation-induced apoptosis targeting and albumin-binding properties. In particular, the prodrug binds circulating albumin after intravenous administration and then activated by caspase-3, which is upregulated from apoptotic cells that responded to radiotherapy. The prodrug was designed to bind circulating albumin to extend half-life and facilitate tumor accumulation in order to increase the possibility of contacting caspase-3, which is only transiently upregulated during apoptosis. Our results showed that EMC-DEVD-S-DOX had a prolonged half-life with enhanced tumor accumulation, which clearly benefited the therapeutic effect of the prodrug. Also, agreeing with the in vitro studies that showed ignorable cytotoxic effect in the absence of caspase-3, the prodrug was effective only when combined with radiotherapy without any noticeable systemic toxicity in vivo. Due to the highly selective action of EMC-DEVD-S-DOX independent to the complex genomic profiles of tumor, the prodrug would overcome the limitation of current targeted therapy and potentiate radiotherapy in the clinical oncology.

AB - Existence of the genomically and epigenomically diverse subclones in a tumor severely limits the therapeutic efficacy of targeted agents. To overcome such a limitation, we prepared a novel targeted prodrug, EMC-DEVD-S-DOX, which comprises two important features: radiation-induced apoptosis targeting and albumin-binding properties. In particular, the prodrug binds circulating albumin after intravenous administration and then activated by caspase-3, which is upregulated from apoptotic cells that responded to radiotherapy. The prodrug was designed to bind circulating albumin to extend half-life and facilitate tumor accumulation in order to increase the possibility of contacting caspase-3, which is only transiently upregulated during apoptosis. Our results showed that EMC-DEVD-S-DOX had a prolonged half-life with enhanced tumor accumulation, which clearly benefited the therapeutic effect of the prodrug. Also, agreeing with the in vitro studies that showed ignorable cytotoxic effect in the absence of caspase-3, the prodrug was effective only when combined with radiotherapy without any noticeable systemic toxicity in vivo. Due to the highly selective action of EMC-DEVD-S-DOX independent to the complex genomic profiles of tumor, the prodrug would overcome the limitation of current targeted therapy and potentiate radiotherapy in the clinical oncology.

KW - Albumin

KW - Apoptosis

KW - Caspase

KW - Drug delivery

KW - Prodrug

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84962812152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962812152&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2016.03.043

DO - 10.1016/j.biomaterials.2016.03.043

M3 - Article

C2 - 27085176

AN - SCOPUS:84962812152

VL - 94

SP - 1

EP - 8

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -